Welcome to our dedicated page for Repare Therapeutics news (Ticker: RPTX), a resource for investors and traders seeking the latest updates and insights on Repare Therapeutics stock.
Repare Therapeutics Inc. (Nasdaq: RPTX) is a clinical-stage precision oncology company whose news flow centers on synthetic lethality-based cancer drug development, portfolio monetization, and a planned acquisition by XenoTherapeutics, Inc. Company press releases describe a pipeline that includes RP-3467, a Phase 1 Polθ ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor, as well as prior development of the PKMYT1 inhibitor lunresertib. News items frequently cover updates on the POLAR and LIONS clinical trials, scientific presentations, and strategic transactions.
Investors and researchers following RPTX news can expect detailed announcements on clinical trial milestones, such as enrollment updates and initial safety, tolerability and early efficacy data from Phase 1 studies. Repare’s disclosures also highlight licensing and collaboration agreements, including an exclusive worldwide license of lunresertib to Debiopharm and an out-licensing of discovery platforms and intellectual property to DCx Biotherapeutics. Additional coverage includes the asset purchase agreement with Gilead Sciences for the Polθ ATPase inhibitor RP-3467 and amendments to collaboration arrangements with partners such as Bristol-Myers Squibb.
A significant portion of recent news focuses on Repare’s strategic review and corporate transactions. The company has announced a definitive arrangement agreement under which XenoTherapeutics, Inc. and Xeno Acquisition Corp. will acquire all of Repare’s common shares through a court-approved plan of arrangement. Related releases describe expected cash consideration per share, the issuance of non-transferable contingent value rights, support and voting agreements with major shareholders, and anticipated delisting from the Nasdaq Global Select Market following closing.
This news page aggregates these company-issued updates, including business highlights, quarterly financial results, conference abstracts and presentations, and regulatory disclosures referenced in Form 8-K filings. Readers interested in RPTX can use this stream to monitor developments in Repare’s precision oncology programs, its partnerships, and the progress of the proposed acquisition and associated contingent value right structure.
Repare Therapeutics presented initial data from its ongoing Phase 1/2 TRESR clinical trial for camonsertib (RP-3500), an ATR inhibitor, in combination with PARPis at the 2023 AACR Annual Meeting. The trials show a 48% clinical benefit rate across various tumor types, especially in late-line ovarian cancer with a 58% clinical benefit rate and a median progression-free survival of about 7 months. Early ctDNA responses indicated a strong antitumor activity, with 66% of evaluable patients responding positively. The treatment showed a favorable safety profile with manageable toxicities. Repare is focused on optimizing doses and expanding studies in different tumor types as part of its collaboration with Roche.
Repare Therapeutics Inc. (Nasdaq: RPTX) announced that data from Phase I/II trials of camonsertib in combination with PARP inhibitors has been selected for presentation at the 2023 AACR Annual Meeting in Orlando, Florida, from April 14-19, 2023. The presentation will highlight safety and efficacy results in patients with solid tumors with DNA damage response alterations, featuring Dr. Timothy Yap. Additionally, two poster presentations will characterize genomic features in ovarian and uterine cancers. Repare's SNIPRx® platform enables the development of precision oncology therapies targeting genomic instability, showcasing its commitment to innovative cancer treatment.
Repare Therapeutics reported its financial results for Q4 and full year 2022, emphasizing growth in its oncology pipeline. The company secured a collaboration with Roche for camonsertib, received FDA Fast Track designation for RP-6306, and expects significant clinical trial data in 2023. Revenue from collaboration agreements rose to $131.8 million in 2022, up from $7.6 million in 2021. Net loss was $31.7 million for Q4 2022, marking an increase from $28.3 million in Q4 2021. Cash and equivalents totaled $343.9 million, projected to support operations until 2026. Repare plans to advance multiple clinical programs throughout 2023.
Repare Therapeutics Inc. (Nasdaq: RPTX) announced its participation in two investor conferences: the Guggenheim Oncology Conference on February 9, 2023, at 3:20 p.m. ET in New York, and the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 9:50 a.m. ET in Boston. Investors can access live webcasts of the events via the Company’s website, with replays available for 30 days. Repare is focused on precision oncology, using its proprietary SNIPRx® platform for developing targeted cancer therapies, including ongoing Phase 1 trials of RP-6306 and camonsertib (RP-3500), and additional preclinical programs.
Repare Therapeutics Inc. (NASDAQ: RPTX) announced a $1.5 million research service payment from Ono Pharmaceutical Co., Ltd. This payment is part of their 2019 Strategic Partnership Agreement, linked to the Polθ program (RP-2119). The funding indicates a key milestone as Repare progresses towards IND-enabling studies and prepares for clinical trials anticipated to start in summer 2023. To date, the Ono Agreement has facilitated approximately $8.1 million in funding for Repare, evidencing ongoing collaboration and financial support for its oncology research initiatives.
Repare Therapeutics Inc. (RPTX) announced the establishment of Automatic Securities Disposition Plans (ASDPs) for its executives, allowing them to sell up to 422,512 common shares over approximately 15 months. This move complies with U.S. and Canadian regulations, ensuring trades occur only when the executives do not possess any material non-public information. The ASDPs provide structured selling parameters while limiting amendments to prevent insider trading advantages. The company is focused on precision oncology, utilizing its SNIPRx® platform to develop therapies for genomic instability.
Repare Therapeutics reported Q3 2022 financial results, achieving a net income of $75.5 million, or $1.71 per diluted share, compared to a net loss of $30.9 million the previous year. The company holds $370.4 million in cash, sufficient to fund operations into 2026. Key developments include advancing RP-6306 in Phase 1 trials, with early data expected in H1 2023, and a collaboration with Roche for camonsertib, which includes a $125 million upfront payment and potential total milestone payments up to $1.172 billion.
Repare Therapeutics Inc. (NASDAQ: RPTX) has announced participation at two upcoming investor conferences in November 2022. The first is the H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference on November 14 at 10:00 a.m. ET. The second is the Piper Sandler 34th Annual Healthcare Conference on November 29 at 3:00 p.m. ET, taking place in New York, NY. Investors can access live webcasts of both events on the Company’s website, with replays available for 90 days. Repare focuses on precision oncology and utilizes its proprietary SNIPRx® platform for novel cancer therapies.
Repare Therapeutics Inc. (NASDAQ: RPTX) will participate in two investor conferences in September 2022. The first event is the Morgan Stanley 20th Annual Global Healthcare Conference on September 14 at 2:55 p.m. ET in New York. The second is the Guggenheim Nantucket Therapeutics Conference on September 28 at 8:00 a.m. ET in Nantucket, MA. Live webcasts will be available on the company’s website, and replays will be accessible for 90 days. Repare focuses on precision oncology, utilizing its SNIPRx® platform to develop targeted cancer therapies.
Repare Therapeutics has signed a worldwide license and collaboration agreement with Roche for camonsertib (RP-3500) aimed at advanced solid tumors. Repare received a $125 million upfront payment and could earn up to $1.172 billion in milestones, plus royalties on global sales. The company expects clinical data for RP-6306 in early 2023, having initiated IND-enabling studies for RP-2119. Financial results show a net loss of $38.1 million for Q2 2022, up from $26.3 million in Q2 2021, despite increased R&D investments aimed at advancing its oncology pipeline.